Mislabeled Bottles Trigger Recall of the ADHD Drug Zenzedi
By Physician’s Briefing Staff HealthDay Reporter
TUESDAY, Jan. 30, 2024 -- One lot of Zenzedi (dextroamphetamine sulfate) 30-mg tablets is being recalled after a pharmacist found antihistamine tablets (carbinoxamine) in a bottle labeled as Zenzedi, according to a recall notice issued by Azurity Pharmaceuticals Inc.
The recall comes amid an ongoing national shortage of attention-deficit/hyperactivity disorder (ADHD) drugs, creating further frustration for people with ADHD who have struggled to find medications for their condition.
The recall notice said that people who take carbinoxamine instead of Zenzedi have a higher risk for accidents or injuries and may have drowsiness, increased eye pressure, urinary obstruction, and thyroid disorder. The recalled lot has the lot number F230169A and an expiration date of June 2025.
Azurity added that it has not received any reports of serious injury related to the medication mix-up.
Consumers who have the recalled medication should return it to their pharmacy. Any adverse reactions to the drug should be reported to the U.S. Food and Drug Administration MedWatch Adverse Event Reporting program.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Pharmacological Treatment of ADHD May Cut Some Forms of Criminality
WEDNESDAY, May 29, 2024 -- Pharmacological treatment may reduce some types of criminality among adolescents and young adults with attention-deficit/hyperactivity disorder (ADHD)...
One in Nine U.S. Children Have Ever Been Diagnosed With ADHD
THURSDAY, May 23, 2024 -- Diagnoses of attention-deficit/hyperactivity disorder (ADHD) in U.S. children continue to increase, with approximately one in nine having ever received a...
Prenatal Opioid Exposure Not Tied to Neuropsychiatric Disorders in Offspring
THURSDAY, April 25, 2024 -- Prenatal opioid exposure seems not to be associated with a meaningful increase in the risk for neuropsychiatric disorders in offspring, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.